Tag Archives: Global

Hot Investor Mandate 3: Venture Capital Firm with Strong Connections to China Seeks to Invest in Global, Early-Stage Biotech Companies with Opportunistic Outlook

21 Jun

A venture capital firm founded in 2014 has an office in the West Coast with its parent company based in Hangzhou, China. The firm currently has invested in over 39 companies across a wide variety of sectors including biotech, IoT, AI, etc. The firm’s strong connection with Chinese partners enables the firm to support companies with market entry in China. The firm is currently allocating out of its first fund of $20M and prefers to participate in seed/pre-series A financing rounds with check sizes of no larger than $500K.

The firm is currently raising a second fund with a target size of $50M, through which the firm hopes to invest more capital in later rounds (i.e. Series A to B) and provide follow on investments to portfolio companies. Through the second fund, the firm is also seeking to expand their interests in diagnostics, digital health, and novel therapeutics. Early in 2018, the firm has launched an accelerator program to support the growth of early-stage companies in the sectors mentioned above and provide these companies with valuable resources. The firm seeks investment opportunities globally.

The firm is opportunistic and will seek companies in all parts of the life sciences space: therapeutics, medical devices, diagnostics, healthcare IT, etc. The firm has not invested in therapeutic products so far but is actively seeking new opportunities in the biopharma space, focusing on pre-clinical to phase I assets. The firm focuses on early-stage deals and will consider pre-FDA device products. The firm is open to companies developing products in all indications.

The firm seeks to work with privately owned companies with experienced management teams with a track record of success. The firm likes to see companies with intentions of entering the China market as the firm has a network of resources to support this, but this is not a requirement. The firm generally acts as the co-investor in financing rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 4: Corporate Venture Arm of Global Pharma Seeks Therapeutics Companies with Focus on Pre-IND Assets in All Indications

21 Jun

A financially driven corporate life science venture fund of a global pharmaceutical company, invests with the purpose of fostering innovation, driving significant patient benefit, and generating superior returns by creating and investing in innovative life science companies at various stages of their development, independent from the corporate’s strategy. The firm has offices in USA and Europe, and focuses its investment activities in these countries. The firm typically makes equity investments in early venture rounds, investing up to $25 million over multiple financing rounds with 6-8 investments in any given year.

The firm invests in therapeutics with a focus on pre-IND assets and Series A investment rounds. The firm is interested in all classes and indications of innovative therapeutics with paradigm shifting potential.

The firm invests exclusively in privately held companies and aims to be a lead or co-lead with a director position.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 4: Germany-Based CVC with a Global Presence Invests in Innovative Medical Technologies Globally, Including Imaging & PoC and In Vitro Diagnostics

7 Jun

A corporate venture firm is headquartered in Munich, Germany, with additional offices worldwide. The fund invests in medical technology companies that are strategically relevant to the corporate’s interests. Investments in equity rounds range from $1-5 million and are made worldwide.

The firm’s primary focuses within healthcare are medical imaging (including both equipment and software) and diagnostics (particularly point of care diagnostics and molecular diagnostics). In these sectors, the firm focuses on products used in a hospital setting. The firm also invests in digital health solutions that add value to imaging and diagnostics, such as data-as-a-service products. The firm is potentially interested in medical robotics. The firm will invest in any medical indication area, and only invests in companies that have attained proof of concept data for their product, with a preference for companies that have a product on the market that can demonstrate traction and revenue.

The firm generally does not attach strategic rights to an investment other than the right to be informed if the company is seeking a buyer. The firm requires a board seat or a board observer in each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: Healthcare Subsidiary of Large European Company Seeks Global Opportunities of All Stages that Address Chronic Medical Conditions

24 May

A wholly-owned subsidiary of a large conglomerate based in Western Europe is engaged in advancing the role of nutritional therapy to change the course of health for consumers, patients and our partners in healthcare. The firm invests in life science assets at various stages of development through collaboration, in-licensing, or M&A. The company’s allocations are varied in both size and structure, and the company is open to partnerships globally.

The firm has a strong foundation of enteral and oral nutrition products in Aging Medical Care, Critical Care & Surgery, and Pediatric Medical Care (including inborn errors of metabolism) and endeavors to develop nutritional solutions to address chronic medical conditions in the area of gut health, metabolic Health, healthy aging, and allergy. For partnering, the company currently focuses on product opportunities and technologies (i.e. microbiome) that address the same, including our acute care interests, and that also elevate the role of nutrition or leverage natural approaches to prevent and treat conditions that impact consumers and patients alike.

The firm is seeking competent teams with science-based nutritional solutions to deliver improved personalized health care for people with medical conditions. Collaborators can benefit from working with the the firm’s vast R&D network, including a dedicated R&D Center located in Bridgewater, New Jersey.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: San Francisco-based Large Global Private Investment Firm Seeking Early-Stage Therapeutics and Commercial-Stage Devices Worldwide

10 May

A large PE/VC is investing in life science innovation through its $5B Growth and Rise funds. The firm is a leading global private investment firm with over $59 billion AUM, based in San Francisco, California. The investment size typically ranges from $20M to $50M in equity. The firm is agnostic to company location or stage.

The firm aims to invest in therapeutics, commercial stage medical devices, and opportunistically in other innovative life sciences spaces. For therapeutics, the firm seeks small molecules and biologics and is open to all indications including orphan indications. The firm will consider products in all phases of clinical trials, from pre-clinical to phase III, and also commercial stage therapeutics. The firm is open to both PMA and 510K devices, as long as the device is already being sold at a commercial stage. The firm is also interested in services such as CROs and CMOs as well as tools of genomics and proteomics.

The firm invests for the long term, and is heavily involved in, and committed to, the growth and success of their portfolio companies. The firm, therefore, generally take a board seat/observer rights. The firm only invests in private companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 1: China-Based Family Office Seeks Global Investment and In-Licensing Opportunities with Focus in USA & UK

26 Apr

A venture capital fund/family office based in Hangzhou, China currently manages two venture funds in addition to a number of private capital accounts through which investments are made – these two funds focus on life sciences. The firm primarily makes equity investments in early-stage rounds ranging from $1 million initially; for later-stage to pre-IPO companies, the firm looks to make initial equity investments ranging from $3-5 million. The firm looks for companies located around the globe, with a preference in the US and Europe (UK). Currently, the firm is also actively seeking in-licensing opportunities in biotech innovations that has a China angle. The firm is actively looking for investment opportunities.

The firm is a flexible and opportunistic investor and will consider therapeutics, medical devices, and diagnostics. The firm is open to all kinds of sectors and indications. For therapeutics, the firm has specific focuses on novel candidates for disease, PD1-base approaches, gene therapy, oncology, cardiovascular diseases, and small molecules. For medical devices, the firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is also interested in diagnostics although this area is less of a focus. In terms of therapeutics, the firm will look at products of pre-clinical stage and later stages from phase II to phase III. Regarding medical devices, the firm will invest at any stage of development.

The firm is looking for private companies only. The firm typically has no specific requirements for the management team, but this depends on how much the firm invests. The firm looks to take a board seat following the investment and is comfortable acting as both a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: Japanese Pharma Launches New Global Initiative to Invest in Early-Stage Companies

26 Apr

A wholly-owned subsidiary of a global pharmaceutical company with headquarters in Japan is focused on developing innovative products in CNS, dermatology, and pain management. In particular, the pharma has established a strong global presence in transdermal patch products, and has several established products on the market.

The pharmaceutical company is seeking novel products for potential in-licensing and partnering opportunities to strengthen their current pipeline. In addition, the company is unveiling a new initiative through which the company will provide investment to early-stage technologies for which the company could help leverage clinical development. The size of investment will largely depend on the company’s stage of development, but the company is open to invest in seed to mid-stage companies. The company is seeking global opportunities.

With the new early-stage investment initiative, the company is interested in investing and partnering beyond the current focus areas: pain, CNS, and dermatology. Because of the company’s deep expertise in transdermal technology, the company can add significant values to companies with NCEs which can be delivered by patches. The company is also interested in reformulation and repositioning opportunities. The company will consider technologies as early as in development/pre-clinical.

The company has no specific management team requirements. The company has a development and regulatory team that can help companies with advancing towards FDA approval as well as Asian market entry, particularly Japan. Because the company has many resources and support to offer to early-stage companies, experienced management team and successful track record would be a plus, but not a requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: